HAIKOU CITY, Hainan Province, China, May 31 /Xinhua-PRNewswire/ -- China Pharma Holdings. announced it had started distribution of Hepatocyte Growth-promoting Factor (pHGF) after receiving regulatory approval from China’s State Food and Drug Agency (SFDA).
pHGF is an extracted and purified peptide that promotes repair and growth in liver cells and it is indicated for the adjunct treatment of hepatitis at various stages. This product is manufactured at the company’s GMP facility in Haikou and it is currently available as an injectable form in 20mg per vial strength.
According to recent data by WHO, Hepatitis B is a serious health problem in China with carrier rate of around 10 percent, among one of the highest in the world.
About China Pharma Holdings, Inc.
China Pharma Holdings Inc. is a U.S. public company currently listed on the OTC Bulletin Board. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty bio-pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. Helpson develops, manufactures, and markets a broad array of generic and brand products. Helpson’s products are marketed in China and are used to fight against Infections, Cardiovascular, CNS and other prevailing diseases.
FORWARD-LOOKING STATEMENTS
This release contains certain “forward-looking statements” relating to the business of China Pharma and its subsidiary companies, which can be identified by the use of forward-looking terminology such as “believes, expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, regulatory actions or delays, the ability to obtain or maintain intellectual property protection, market acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. China Pharma is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
CONTACT: Donald Xu, +1-858-776-8880, dxu@chinapharmaholdings.com
China Pharma Holdings, Inc.
CONTACT: Donald Xu of China Pharma Holdings, Inc., +1-858-776-8880, ordxu@chinapharmaholdings.com
Web site: http://www.helpson.com/
